New insights into the therapeutic options to lower lipoprotein(a).
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or primary human data synthesis.
PubMed 38778431 · doi:10.1111/eci.14254
What was done
Narrative review summarizing current and emerging therapeutic strategies to lower lipoprotein(a) [Lp(a)], including antisense oligonucleotides, small interfering RNAs, apolipoprotein(a) inhibitors, and CRISPR-Cas9 gene editing.
What was found
Conventional lipid-lowering therapies (statins, ezetimibe, PCSK9 inhibitors) show neutral to modest effects on Lp(a). In contrast, targeted therapies directed towards apolipoprotein(a), including pelacarsen, olpasiran, and lepodisiran, achieve Lp(a) reductions of more than 80%. Proof that this reduction lowers cardiovascular mortality and major adverse cardiovascular events depends on ongoing outcome trials.
Why it matters
Clarifies the therapeutic landscape for Lp(a), an independent cardiovascular risk factor with limited response to traditional lipid-lowering drugs.
Limits
Narrative review with no systematic search or primary data synthesis. Clinical cardiovascular benefit of dramatic Lp(a) reduction remains unproven pending outcome trial results.
Cited by
- supports Evidence has not been substantial enough to prove that lowering lipoprotein(a) prevents heart attacks.